• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巨细胞动脉炎中的卡氏肺孢子虫肺炎:病例系列。

Pneumocystis jiroveci pneumonia in giant cell arteritis: A case series.

机构信息

Mayo Clinic, Rochester, Minnesota, USA.

出版信息

Arthritis Care Res (Hoboken). 2011 May;63(5):761-5. doi: 10.1002/acr.20435.

DOI:10.1002/acr.20435
PMID:21240966
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3091984/
Abstract

OBJECTIVE

To describe the clinical presentation, laboratory findings, and outcome of patients with Pneumocystis jiroveci pneumonia (PCP) and biopsy-proven giant cell arteritis (GCA) seen at a tertiary referral center.

METHODS

Using International Classification of Diseases, Ninth Revision codes, all patients with GCA and PCP between January 1, 1976 and December 31, 2008 were identified. Medical records were reviewed. PCP was defined by the identification of Pneumocystis jiroveci organisms in the clinical setting of pneumonia.

RESULTS

We identified 7 patients with GCA (5 women and 2 men) who developed PCP (the mean ± SD age at diagnosis was 71.6 ± 6.1 years). The median time from GCA diagnosis to PCP diagnosis was 3 months (range 1-18 months). All patients were taking prednisone (the median dosage 50 mg/day [range 30-80]) when diagnosed as having PCP. No patients were receiving PCP prophylaxis. PCP was diagnosed by positive smear on bronchoalveolar lavage fluid in 6 patients (86%) and by positive sputum polymerase chain reaction in 1 patient. All the patients were hospitalized (median duration 17 days [range 12-39 days]). Four patients (57%) were admitted to the intensive care unit. Three patients (43%) required mechanical ventilation. Two patients (29%) died; both were on mechanical ventilation.

CONCLUSION

Although PCP is rare among patients with GCA, this preventable infection is associated with significant morbidity and mortality.

摘要

目的

描述在一家三级转诊中心就诊的经活检证实的巨细胞动脉炎(GCA)合并肺囊虫肺炎(PCP)患者的临床表现、实验室检查结果和转归。

方法

使用国际疾病分类,第九版代码,确定 1976 年 1 月 1 日至 2008 年 12 月 31 日期间所有患有 GCA 和 PCP 的患者。回顾病历。PCP 的定义为在肺炎的临床情况下发现卡氏肺孢子虫。

结果

我们共发现 7 例患有 GCA(5 名女性和 2 名男性)并发 PCP(诊断时的平均年龄 ± 标准差为 71.6 ± 6.1 岁)。从 GCA 诊断到 PCP 诊断的中位时间为 3 个月(范围 1-18 个月)。所有患者在诊断为 PCP 时均接受泼尼松治疗(中位剂量 50mg/天[范围 30-80])。没有患者接受 PCP 预防。6 例(86%)患者通过支气管肺泡灌洗液的阳性涂片诊断为 PCP,1 例患者通过阳性痰聚合酶链反应诊断为 PCP。所有患者均住院(中位住院时间 17 天[范围 12-39 天])。4 例(57%)患者入住重症监护病房。3 例(43%)患者需要机械通气。2 例(29%)患者死亡;均在接受机械通气。

结论

虽然 PCP 在 GCA 患者中很少见,但这种可预防的感染与显著的发病率和死亡率相关。

相似文献

1
Pneumocystis jiroveci pneumonia in giant cell arteritis: A case series.巨细胞动脉炎中的卡氏肺孢子虫肺炎:病例系列。
Arthritis Care Res (Hoboken). 2011 May;63(5):761-5. doi: 10.1002/acr.20435.
2
Risk factors for pneumocystis pneumonia in giant cell arteritis: a single-centre cohort study.巨细胞动脉炎患者发生肺孢子菌肺炎的危险因素:一项单中心队列研究。
Clin Exp Rheumatol. 2015 Mar-Apr;33(2 Suppl 89):S-122-5. Epub 2015 May 26.
3
Pneumocystis jirovecii pneumonia in systemic lupus erythematosus from southern Taiwan.台湾南部系统性红斑狼疮合并卡氏肺囊虫肺炎。
J Clin Rheumatol. 2013 Aug;19(5):252-8. doi: 10.1097/RHU.0b013e31829d5017.
4
Evaluation of Toluidine Blue O staining for the diagnosis of Pneumocystis jiroveci in expectorated sputum sample and bronchoalveolar lavage from HIV-infected patients in a tertiary care referral center in Ethiopia.在埃塞俄比亚一家三级医疗转诊中心,对甲苯胺蓝O染色法在诊断HIV感染患者咳出痰液样本和支气管肺泡灌洗样本中的耶氏肺孢子菌的应用进行评估。
Infection. 2008 Jun;36(3):237-43. doi: 10.1007/s15010-007-7191-8. Epub 2008 May 15.
5
A followup study of asymptomatic carriers of Pneumocystis jiroveci during immunosuppressive therapy for rheumatoid arthritis.类风湿关节炎免疫抑制治疗期间耶氏肺孢子菌无症状携带者的随访研究。
J Rheumatol. 2009 Aug;36(8):1600-5. doi: 10.3899/jrheum.081270. Epub 2009 Jun 16.
6
Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host.肾移植受者中耶氏肺孢子菌肺炎的暴发:耶氏肺孢子菌对易感宿主具有传染性。
Transplantation. 2009 Aug 15;88(3):380-5. doi: 10.1097/TP.0b013e3181aed389.
7
Determining the Incidence of Pneumocystis Pneumonia in Patients With Autoimmune Blistering Diseases Not Receiving Routine Prophylaxis.确定未接受常规预防的自身免疫性大疱性疾病患者中肺孢子菌肺炎的发病率。
JAMA Dermatol. 2017 Nov 1;153(11):1137-1141. doi: 10.1001/jamadermatol.2017.2808.
8
Risk factors analysis for Pneumocystis jiroveci pneumonia (PCP) in patients with haematological malignancies and pneumonia.血液系统恶性肿瘤合并肺炎患者发生耶氏肺孢子菌肺炎(PCP)的危险因素分析
Scand J Infect Dis. 2004;36(11-12):848-54. doi: 10.1080/00365540410021180.
9
Cytomegaloviral or Pneumonia Increases Mortality in Systemic Lupus Erythematosus Patients with Pulmonary Hemorrhage: Evidence from Bronchoalveolar Lavage Fluid.巨细胞病毒或肺炎会增加系统性红斑狼疮伴肺出血患者的死亡率:支气管肺泡灌洗液的证据。
J Rheumatol. 2019 Mar;46(3):251-258. doi: 10.3899/jrheum.180104. Epub 2018 Dec 1.
10
Evaluation of a real-time PCR assay for the diagnosis of Pneumocystis pneumonia.一种用于诊断肺孢子菌肺炎的实时聚合酶链反应检测方法的评估
Kurume Med J. 2008;55(3-4):55-62. doi: 10.2739/kurumemedj.55.55.

引用本文的文献

1
Invasive fungal diseases in patients with autoimmune diseases: a case series from the French RESSIF network.自身免疫性疾病患者的侵袭性真菌病:法国 RESSIF 网络的病例系列。
RMD Open. 2023 Aug;9(3). doi: 10.1136/rmdopen-2023-003281.
2
Pneumonia: A Review of Management in Human Immunodeficiency Virus (HIV) and Non-HIV Immunocompromised Patients.肺炎:人类免疫缺陷病毒(HIV)及非HIV免疫功能低下患者的管理综述
Avicenna J Med. 2023 Mar 24;13(1):23-34. doi: 10.1055/s-0043-1764375. eCollection 2023 Jan.
3
Time to trimethoprim/sulfamethoxazole initiation among patients with rheumatic disease complicated by Pneumocystis jirovecii pneumonia: impact on 90-day mortality.风湿性疾病合并肺孢子菌肺炎患者中 trimethoprim/sulfamethoxazole 起始治疗时间:对 90 天死亡率的影响。
BMC Infect Dis. 2022 Dec 27;22(1):961. doi: 10.1186/s12879-022-07940-z.
4
Duration of prednisone treatment before development of pneumonia in patients with vasculitis: A case series.血管炎患者发生肺炎前泼尼松治疗的持续时间:病例系列
J Assoc Med Microbiol Infect Dis Can. 2022 Jun 3;7(2):117-124. doi: 10.3138/jammi-2021-0031. eCollection 2022 Jun.
5
Giant cell arteritis treatment patterns and rates of serious infections.巨细胞动脉炎的治疗模式和严重感染发生率。
Clin Exp Rheumatol. 2022 May;40(4):826-833. doi: 10.55563/clinexprheumatol/uonz1p. Epub 2021 Dec 13.
6
Boundaries of a systemic disease: a protean presentation of giant cell arteritis.一种全身性疾病的边界:巨细胞动脉炎的多样表现
BMJ Case Rep. 2020 Mar 25;13(3):e232234. doi: 10.1136/bcr-2019-232234.
7
Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis.系统文献回顾为 2018 年 EULAR 大血管血管炎管理推荐更新提供信息:重点关注巨细胞动脉炎。
RMD Open. 2019 Sep 16;5(2):e001003. doi: 10.1136/rmdopen-2019-001003. eCollection 2019.
8
Updates in the Diagnosis and Management of Giant Cell Arteritis.巨细胞动脉炎的诊断与治疗进展。
Curr Neurol Neurosci Rep. 2019 Aug 8;19(9):68. doi: 10.1007/s11910-019-0982-3.
9
Therapy and Management of Infection.感染的治疗与管理
J Fungi (Basel). 2018 Nov 22;4(4):127. doi: 10.3390/jof4040127.
10
Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented?卡氏肺孢子虫肺炎与风湿病学家:哪些患者有风险,如何预防卡氏肺孢子虫肺炎?
Curr Rheumatol Rep. 2017 Jun;19(6):35. doi: 10.1007/s11926-017-0664-6.

本文引用的文献

1
A survey of rheumatologists' practice for prescribing pneumocystis prophylaxis.一项关于风湿科医生开预防卡氏肺孢子虫肺炎处方的实践调查。
J Rheumatol. 2010 Apr;37(4):792-9. doi: 10.3899/jrheum.090843. Epub 2010 Mar 1.
2
Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection.免疫抑制患者中合并和不合并 HIV 感染的肺孢子菌肺炎的临床特征差异。
Respirology. 2010 Jan;15(1):126-31. doi: 10.1111/j.1440-1843.2009.01660.x. Epub 2009 Nov 23.
3
Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence?原发性系统性血管炎的抗感染化学预防的价值:有何证据?
Arthritis Res Ther. 2009;11(5):253. doi: 10.1186/ar2826. Epub 2009 Oct 28.
4
Increase in age at onset of giant cell arteritis: a population-based study.巨细胞动脉炎发病年龄的增加:一项基于人群的研究。
Ann Rheum Dis. 2010 Apr;69(4):780-1. doi: 10.1136/ard.2009.111005. Epub 2009 Oct 22.
5
Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection.合并或未合并HIV感染的重症肺孢子菌肺炎患者的重症监护管理及预后
Crit Care. 2008;12(1):R28. doi: 10.1186/cc6806. Epub 2008 Jan 25.
6
Multiple opportunistic infections after high-dose steroid therapy for giant cell arteritis in a patient previously treated with a purine analog.
Scand J Infect Dis. 2006;38(10):922-4. doi: 10.1080/00365540500540475.
7
Pneumocystis pneumonia.肺孢子菌肺炎
N Engl J Med. 2004 Jun 10;350(24):2487-98. doi: 10.1056/NEJMra032588.
8
Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes.巨细胞动脉炎的糖皮质激素治疗:疗程与不良结局
Arthritis Rheum. 2003 Oct 15;49(5):703-8. doi: 10.1002/art.11388.
9
Low-dose methotrexate as a risk factor for Pneumocystis carinii pneumonia.低剂量甲氨蝶呤作为卡氏肺孢子虫肺炎的一个危险因素。
Mil Med. 1996 Jan;161(1):58-60.
10
Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy.在接受免疫抑制治疗的韦格纳肉芽肿患者中预防卡氏肺孢子虫肺炎的成本效益
Arthritis Rheum. 2000 Aug;43(8):1841-8. doi: 10.1002/1529-0131(200008)43:8<1841::AID-ANR21>3.0.CO;2-Q.